Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies

Ravulizumab, a novel long‐acting complement component 5 (C5) inhibitor administered every 8 weeks (q8w), was non‐inferior to eculizumab for all efficacy outcomes in two randomised, open‐label, phase 3 trials in C5 inhibitor‐naïve (Study 301) and eculizumab‐experienced (Study 302) adult patients with...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Br J Haematol
Hauptverfasser: Peffault de Latour, Régis, Brodsky, Robert A., Ortiz, Stephan, Risitano, Antonio M., Jang, Jun H., Hillmen, Peter, Kulagin, Alexander D., Kulasekararaj, Austin G., Rottinghaus, Scott T., Aguzzi, Rasha, Gao, Xiang, Wells, Richard A., Szer, Jeff
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2020
Schlagworte:
Red cells and Iron
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7687070/
https://ncbi.nlm.nih.gov/pubmed/32449174
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.16711
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge